| Biomarker ID | 24 |
| PMID | 10999725 |
| Year | 2000 |
| Biomarker | Caveolin-1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in African American Men (AA: 39% vs WA: 17%) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Endothelial NOS activation,VEGFR1 pathway,Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis,Nitric oxide metabolism,ALK1 pathway |
| Experiment | African Americans vs White American men with Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 71 White American and 71 African American men with Prostate Cancer were compared |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0048 |
| Method Used | Quantitative Immunostaining |
| Clinical | No |
| Remarks | caveolin-1, bcl-2, p53, and c-myc were used as biomarkers to test whether they were differentially expressed in African American vs White men. Only caveolin-1 was found to be Differentially expressed |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on external patient cohort |
| Technical Name | CAV1 |